A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age
Clinical trial NCT06806137 · RECRUITING
Trial details
- NCT number
- NCT06806137
- Sponsor
- GlaxoSmithKline
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-15
- Primary completion
- 2026-12-14
- Enrollment
- 600
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.